SCHEMBL411945

SCHEMBL411945

OC(CCl)CNc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.61
SMN1; SMN2 Q16637 2/20 0.59
HTT P42858 1/20 0.59
DNM1 Q05193 2/20 0.54
KDM4E B2RXH2 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
BCHE P06276 1/20 0.45
LMNA P02545 1/20 0.45
ALDH1A1 P00352 3/20 0.43
ATG4B Q9Y4P1 2/20 0.42
ADRB2 P07550 1/20 0.42
ADRB1 P08588 1/20 0.42
ADRB3 P13945 1/20 0.42
ABCB1 P08183 2/20 0.41
KDM1A O60341 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8369004 1.00 MAPT (0.61) MAPTSMN1; SMN2HTTDNM1KDM4E
Sulfamide SCHEMBL11870110 0.89 MAPT (0.51) MAPTSMN1; SMN2HTTDNM1KDM4E
SCHEMBL7277860 0.89 MAPT (0.68) MAPTSMN1; SMN2HTTDNM1KDM4E
SCHEMBL1298434 0.83 MAPT (0.61) MAPTSMN1; SMN2HTTDNM1KDM4E
SCHEMBL11427950 0.81 BCHE (0.48) MAPTSMN1; SMN2HTTDNM1MEN1
SCHEMBL13838308 0.81 MAPT (0.59) MAPTSMN1; SMN2HTTDNM1KDM4E
SCHEMBL11154614 0.81 MAPT (0.59) MAPTSMN1; SMN2HTTDNM1KDM4E
SCHEMBL5423470 0.81 MAPT (0.65) MAPTSMN1; SMN2HTTDNM1KDM4E
SCHEMBL168120 0.79 MAPT (0.57) MAPTSMN1; SMN2HTTDNM1KDM4E
SCHEMBL7346554 0.79 MAPT (0.58) MAPTSMN1; SMN2HTTDNM1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-10218866-A None JP disclosed
JP-11005786-A None JP disclosed
JP-9278722-A None JP disclosed
CN-109762853-B Method for synthesizing isopropanol beta-alkamine derivative on line by lipase catalysis 浙江工业大学 2021-07-27 CN disclosed
US-10183011-B2 Anti-depression compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-01-22 US disclosed
US-10183011-B2 Anti-depression compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-01-22 US disclosed
US-20180318255-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2018-11-08 US disclosed
CN-108329253-A Preceding neurogenic compounds 得克萨斯州大学系统董事会 2018-07-27 CN disclosed
US-20180127367-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2018-05-10 US disclosed
US-20180127367-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2018-05-10 US disclosed
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-26 US disclosed
WO-2012006419-A2 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-12 WO disclosed
WO-2012006419-A2 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-12 WO disclosed
JP-H115786-A NOVEL AMINOHYDROXYPROPYLPIPERAZINE DERIVATIVE POLA CHEM IND INC 1999-01-12 JP disclosed
JP-H10218866-A AGENT FOR INHIBITING REUPTAKE OF DOPAMINE POLA CHEM IND INC 1998-08-18 JP disclosed
JP-H09278722-A OPTICALLY ACTIVE PROPANOL DERIVATIVE POLA CHEM IND INC 1997-10-28 JP disclosed
US-4215220-A 1-(2-Oxysubstituted-3-anilinopropyl)-imidazoles CILAG-CHEMIE A.G. (CH) 1980-07-29 US disclosed
US-4060544-A COUPLERS GAF CORPORATION (US) 1977-11-29 US disclosed
US-4039524-A Keto-amido containing phenylazo benzothiazole dyestuffs GAF CORPORATION (US) 1977-08-02 US disclosed
US-3931145-A POLYESTER GAF CORPORATION (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BDNF, GAP43, DCX MAPT 136/4885SMN1; SMN2 50/4885HTT 31/4885
US-20180127367-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX MAPT 136/4885SMN1; SMN2 50/4885HTT 31/4885
US-20180318255-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX MAPT 136/4885SMN1; SMN2 50/4885HTT 31/4885
US-10183011-B2 Anti-depression compounds BDNF, DCX, GAP43 MAPT 142/4885SMN1; SMN2 63/4885HTT 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.